Trial Profile

A Phase 1/1b trial of GM1020

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GM 1020 (Primary)
Indications Depressive disorders
Focus Adverse reactions; First in man
Sponsors Gilgamesh Pharmaceuticals

Most Recent Events

15 Dec 2022 According to a Gilgamesh Pharmaceuticals media release, the company announced the closing of a $39 million Series B round of financing and it was led by Prime Movers Lab with additional investment from Alumni Ventures, Palo Santo, Negev Capital, Route 66, JLS Fund, Satori Capital and Gron Ventures. The additional capital will be used to advance GM1020 through this trial.
31 Mar 2022 New trial record
24 Mar 2022 According to a Gilgamesh Pharmaceuticals media release, GM1020 will soon complete IND enabling toxicology studies with Phase 1 trial expected to begin in the second half of 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com